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Table 1 [Document No. (2009)-84] General Office of the
Ministry of Health of P.R. China: The first batch of Class III
medical techniques approved for clinical use [7].
No. Name Technical review
institutions
Clinical use
review
departments
19 TE techniques Provincial health
departments
notified bodies
Provincial
health
departments
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As physical injuries, chronic diseases, and degenerative
disorders associated with elderly patients become more
prevalent in China [1], transplantation is regarded as ideal
treatment for traumatic injury or surgically created de-
fects; however, the shortage of transplant tissue/organs
greatly restricts its application [2]. Tissue engineering (TE)-
based regenerative medicine strategies are emerging as
promising therapeutic modalities, which apply a combina-
tion of cells, scaffolds, and bioactive factors to restore,
maintain, or improve the tissue structure and function [3].
Studies on TE are growing quickly in China, and a large
number of promising findings have been reported in the
literature, especially in the highly translational orthopaedic
and musculoskeletal research [4,5]. However, few results
from these studies have been introduced into clinical
application [5]. To fill the gap between the bench and
bedside, multidisciplinary issues must be addressed. It is a
cooperative work that should integrate participants with
different disciplines and experiences [6].
The translational channel of TE technique applications is
different from transplanted tissues, biologics or pharma-
ceuticals, but has some similarities. The general procedure
includes technique/product design and development,
quality management, clinical trials, application regulation
and registration, and pricing and marketing [7]. Moreover,
depending on the specificity of target tissue, each tech-
nique may have its own requirements. Researchers may be
familiar with the good expertise at the science and product
development stage, but often encounter problems upon
reaching the later stages. With the uniting of the scientists,
engineers, clinicians, regulatory experts, and business ex-
ecutives from different backgrounds, our group successfully
translated an autologous cell-based TE technique into
clinical therapy for the first time in China in 2010. Here we
would like to discuss the systematic requirements, and
share our experience and lessons, to give an example of the
translation procedure of TE techniques in China for re-
searchers who are interested in and wish to take further
steps in their own research work.TE techniques are categorised as Class III
medical techniques and approved for clinical
use
OnApril 21, 2009,TE techniquesbecamethefirst batchofClass
III medical techniques approved for clinical use in China
[DocumentNo. (2009-84)] [8]. Thedetails are shown inTable 1.
This document officially admits TE techniques into
clinical practice, and clearly specifies the responsible de-
partments. Notably, the province-level, but not state-level
health departments undertake the technical and clinical-
use review procedure, indicating the lower risk and higher
efficiency of TE techniques translation.
General procedure
For TE techniques, there are several steps to be accom-
plished prior to obtaining clinical approval (Fig. 1).Technique provider
The technique provider (i.e., TE research centre, high-tech
enterprise) should carry out comprehensive preclinical
studies to fully demonstrate the safety and efficacy of their
techniques, including physical, chemical, and biological
testing. After internal self-examination, official test reports
from external bodies are needed in accordance with the
prevailing industrial standards. In China, we obtained test
reports for cell biologics from the National Institute for Food
and Drug Control (NIFDC), and for Class III medical devices
from the provincial medical device supervising and inspection
centre of the China Food and Drug Administration (CFDA).
Contract manufacturer
Contract manufacturer must ensure the manufacturing envi-
ronment be certified by the provincial Food and Drug Admin-
istration (FDA) or higher supervisory body, and in accordance
with the code of good manufacturing practice (cGMP) for
sterile medical products. Standard Operating Procedures
(SOPs) are needed for management and quality control. The
SOPs directory will be provided in the following section.
Hospital
Under a specific guideline for Class III TE techniques
[Document No. (2009)-199], the hospitals (must be tertiary
hospitals) who want to use the specific technique for human
therapy should apply for clinical approval from the pro-
vincial health department and provide appropriate training
for their clinicians in that specific technique platform.
Guideline for Class III TE techniques
Guideline for transplantation and treatment with TE tech-
niques was issued by the Ministry of Health of P.R. China on
Nov 13, 2009 [9]. The full text was translated into English as
follows:
“Document No. (2009)-199
Ministry of Health of P. R. China: Guideline for
Transplantation and Treatment with TE Techniques
(Trial Version)” [9]
“.This document is intended to provide criteria for
technical review and clinical application, and to ensure the
safety and effectiveness of TE techniques. Hospitals and
affiliated doctors who seek permission to implement these
techniques must comply with this document.
“.The TE techniques referred to here are therapeutic
modalities utilizing artificially engineered tissues that
contain autologous bioactive cells and are transplanted to
repair, improve and restore the structure and/or function
Figure 1 Translation procedures for tissue engineering products/techniques. cGMP/SOPZ code of good manufacturing practice/
Standard Operating Procedure.
58 W. Zhang et al.of tissues or organs within the human body. It does not
include the direct transplantation (i.e., autologous carti-
lage, dermatoplasty, etc.) of live or preserved cells, tis-
sues and organs, as well as somatic cell therapy for other
purposes. At present, tissue-engineered techniques are
only applicable for clinical restoration of structural tissues
(i.e., bone, cartilage, skin, etc.), but are prohibited for
more complex tissues such as liver, kidney, brain that have
higher metabolic rates.
Basic requirements for hospitals and processing
environment“
. (1) Hospitals
a. Hospitals utilizing TE techniques should be qualified to
perform their functions and tasks.
b. These should be tertiary hospitals established with
authorized departments of orthopaedics, plastic surgery,
burn, neurosurgery, ophthalmology, stomatology, and
other departments that have the demand for TE thera-
pies, as well as clinical laboratory, x-ray room, pathology
department and other supporting departments and fa-
cilities for follow-up visit and examination.
c. Standardized and operational ethics committee for TE
techniques should be set up with medical, legal, and
ethical experts.
“.(2) Processing environment
a. The environment should be a cleanroom certified for
human cell processing by the provincial FDA or above,
and in accordance with cGMP for sterile medical prod-
ucts (YY0033-2000).
b. cGMP human cell processing cleanroom
a) The cleanliness class should be more than 10,000 for the
whole environment, and 100 for the cell culture and
tissue fabrication area.
b) The cleanroom should be well-organized and suitable for
cell culture and tissue fabrication. Personnel and ma-
terial flow should be isolated and well-controlled.c) The cleanroom should be well-equipped for tissue/cell
collection, isolation, culture, identification, processing
and preservation. Cross-contamination should be pre-
vented by strict rules and measures.
d) SOPs should be set up for each step of cell processing.
Key procedures, quality control standards and test in-
dexes should be determined. A regulated and complete
quality management system (QMS) should be
established.
“.There should be at least two in-service doctors with
expertise in clinical translation of TE techniques, as well as
some other professionals who have received appropriate
training and are proficient in TE techniques.
Basic requirements for personnel
“. (1) Doctors
a. Acquire the certification as medical doctor and practice
in TE related fields.
b. In-service doctors with minimal qualification as asso-
ciate chief clinician and are qualified for clinical
application of TE techniques.
“. (2) Other professionals
a. At least one director with a minimal qualification of
associate professor with TE expertise.
b. Cell processing personnel must acquire at least a college
education in a relevant expertise, have the theoretical
knowledge and practical skills of cell biology and TE,
and be qualified through appropriate training and
assessment.
c. Quality control personnel must acquire at least a col-
lege education of a relevant expertise, and be qualified
through appropriate training and assessment.
Basic requirements for technique management
“. (1) Establish the QMS for TE techniques. Establish
the test methods and evaluation criteria for the key
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niques, including the seed cells, scaffold materials,
bioactive factors, and microenvironment.
a. Set the quality control specifications for human-derived
cells
The QMS referred here is only applicable to autologous
cells for engineered tissues. Allogeneic cells are not
allowed for clinical use.
According to the Pharmacopoeia of the People’s Re-
public of China, Guideline for the Research and Quality
Control of Human-derived Cells and General Principle for
Cell Culture issued by CFDA, the quality control specifi-
cations for human-derived cells are established. The basic
requirements include the donor source, cell culture SOPs,
specifications for cell processing and evaluation to ensure
traceability and stability. The testing parameters should
include cell collection, isolation and identification, cell
culture medium, cell purity, cell viability, homogeneity,
biological effect, exogenous factor, and presence of
pathogenic microorganisms (i.e., endotoxin, bacteria,
fungi and mycoplasma).
b. Setting the quality control specifications for scaffold
materialsFigure 2 Clinical approval proceduresThe materials that are utilized in TE techniques must be
certified with a test report from the medical device su-
pervising and testing center of CFDA, which includes
physical, chemical and biological properties.
c. Setting the quality control specifications for engineered
tissue
According to the pharmaceutical industry standard of
the People’s Republic of China Tissue Engineered Medical
Product (YY/T0606-2007), the fabrication processes
including cell seeding, tissue culture and engineered tissue
fabrication should be under stringent quality control.
Quality control specifications and relevant SOPs should be
set up to ensure the safety and effectiveness of clinical
translation of TE techniques.
“. (2) The appropriate treatment plan should be based
on the patient’s condition, available treatment modal-
ities, patient preference and financial capacity. The in-
dications and contraindications should be emphatically
considered.
“. (3) A specialized TE treatment procedure should be
co-determined by technicians and clinicians with at least
associate professor qualifications. Rational treatment and
management plan including precautions for failures and
complications should be made.for Class III cartilage TE technique.
Table 2 Checklist of the application documents for Class
III cartilage TE technique [13].
No. Category Content Preparation
1 Introduction General information of
applicant medical institution
2 Personnel Technical personnel
Program personnel
Program leader
Primary personnel
3 Facility Specialised equipment,
facilities, and the work
experience of relevant
departments
Supporting facilities
4 Program Introduction
Purpose and significance
Embodiments
Specific operating standards
5 Treatment General information about
the technique
Domestic and worldwide
application
Indications
Contraindications
Adverse reactions
6 Technique Technical routes
Quality control measures
Clinical criteria and
assessment methods
Comparison with other
alternative treatments (risk,
effect, charge, time, etc.)
7 Ethics Comments from ethics
committee
Attachment
1 Institution The Practice License of
Medical Institution (copy)
General information about
medical institution (including
number of beds, personnel,
equipment, facilities,
techniques, etc.)
2 Ethics Examination report from the
ethics committee
Ethics committee member list
(including name, workplace,
major, position, title etc.)
3 Management Management system and
quality control measures
4 Treatment Informed consent
Risk evaluation and
emergency plan
5 Pre-clinical Clinical trial report
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dure, doctors should inform the patients and their family
members of the purpose, risk, postoperative care, possible
complications, appropriate precautions and alternative
treatment options. The patients should sign the informed
consent form.
“. (5) Hospitals should set up a complete clinical
database with strict postoperative follow-up system.
“. (6) Hospitals and doctors should receive regular
inspection for clinical application of TE techniques. The
inspection includes case selection criteria, treatment ef-
ficacy, severe complications, morbidity, medical accidents,
postoperative patient management, patients’ life quality,
follow-up visit, and patient records.
“. (7) Other management requirements
a. Utilize the CFDA or state-level FDA-approved medical
device. Set the registration system to ensure trace-
ability. In the isolation and culture procedure, single-
use devices should only be used once and cannot be
reused for tissues and cells derived from different
sources.
b. Strictly regulate the price and fiscal policies Fees should
be charged according to the provision of relevant med-
ical procedures.”
This guidance document was developed as a special
control guidance to support the technical review and clin-
ical application of TE techniques, and provides specific
requirements regarding the hospitals, processing environ-
ment, personnel, and technique management. It not only
directs the applicant hospitals for data preparation,
establishment equipment, personnel education, and pro-
gram management, but also guides the regulatory bodies
for standard and efficient review and surveillance. The
hospitals that seek permission for TE techniques imple-
mentation must address all issues identified in this guidance
by meeting the minimum requirements.
Clinical translation of cartilage TE
techniquedA Zhejiang province model
According to the guidelines, by coordinating the technique
provider, contract manufacturer, and hospitals, our
research group launched the autologous chondrocyte-based
cartilage TE technique in Zhejiang province since 2010, and
this is now implemented in the five largest tertiary hospitals
in Zhejiang Province. Notably, it is the first batch of
authorised clinically approved TE techniques in China.
Cartilage tissue is a physiologically non-self-renewing,
avascular tissue with a singular cell type, the chondrocytes,
which functions as the load-bearing joint surface. Trauma
or diseases that cause cartilage degradation often lead to
osteoarthritis. The therapeutic function of autologous
chondrocyte transplantation for cartilage defect repair was
established in the 1980s, and the clinical report was pub-
lished in 1994 [10], The overall zero to 5-year therapeutic
efficacy is 70e90% in general, as evidenced by relief of
symptoms and improvement of joint function [11]. A recent
report has shown that after up to 20 years of follow up,
good results are maintained [12]. The TE technique forcartilage repair was developed to reduce the open injury
site and shorten the surgical time; biomaterials were
introduced as the second generation of autologous chon-
drocyte implantation/transplantation (ACI/ACT); and an
“all in one” graft that combined the seed cells and
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either periosteal cover or fixing sutures, which was defined
as matrix-associated autologous chondrocyte implantation/
transplantation (MACI or MACT) [11]. We obtained the
preclinical data, retrieved the test report for autologous
chondrocyte from NIFDC, and obtained the cGMP report for
processing in a clean-room from Zhejiang FDA. After the
technological and production procedures were performed,
we helped the prospective hospitals apply for clinical
approval. Here we elaborate on the clinical application
process [13] (Fig. 2).Overview of the application procedure
Preparation and application
The orthopaedic department of the applicant tertiary hos-
pitals prepares all the required materials, equipment, and
personnel according to the Guideline for Transplantation
and Treatment with TE Techniques [Document No. (2009)-
199]. After obtaining approval from the hospital ethics
committee, the orthopaedic department submits the
application to provincial regulatory bodies for clinical use
qualifications of cartilage TE technique.
Review and examination
The application is examined by the expert committee of
the Health Bureau of Zhejiang Province according to the
Guideline for Transplantation and Treatment with TE
Techniques [Document No. (2009)-199]. If the application is
not approved, the applicant hospital should improve the
programme based on the rejection notification and resub-
mit the application.
Cost and charging
If the hospital is qualified and passes the acceptance re-
view, the approved hospital performs appropriate cost ac-
counting and is examined and approved by both the
Zhejiang Provincial Price Bureau and the Health Bureau of
Zhejiang Province. Then the orthopaedic department of the
applicant hospital can implement the cartilage TE tech-
nique with officially charging.Figure 3 Document management directorieChecklist of the application documents
Here we summarise the checklist of the application docu-
ments. The applicant hospitals should check every detail
before submitting the application (Table 2).Document management system
To ensure consistent quality control of cartilage TE tech-
nique, a complete document management system should
be established. In our case, we adopted the experience
shared by Mayhew et al [14]. Under the GMP documentation
management principle, we designed and established our
document management system (Fig. 3). Here we also share
our main documents list as a reference for future TE
technique contributors (Table 3).The challenges for clinical translation of TE
techniques
The cultured autologous chondrocytes for ACI was approved
by the FDA as biological products in 1997 [15], and the
general cell-based therapies development pathway was
well established [16]. However, in China, regulations were
lacking for a couple of years. Thus, we tried to unite the
scientists, engineers, clinicians, regulatory experts, busi-
ness executives; connected and communicated with the
research centres, the university hospitals, the industry
companies and the government administrations; proposed,
established, and finally carved a translational pathdthe
Class III autologous cell-based TE techniques.
Our successful bench-to-bedside (B2B) translation
experience of autologous chondrocyte-based cartilage TE
technique is a milestone in China, which proved the feasi-
bility and implicates the possibilities for the future appli-
cation of more TE techniques. This is a start of
industrialisation, and we need to realise that there will be
more hurdles along the way, in the quest for more inno-
vative researchers, entrepreneurs, supervisors, adminis-
trators, and translational experts to turn them intos. SOPs Z standard operating procedures.
Table 3 Document management list [13].
1. Standards
1.1 Management standards (M e Management; C e Center; H e Human resource)
MS-M-001 Organisational chart
MS-M-002 Sterilisation management
MS-M-003 Production area maintenance
MS-M-004 Equipment maintenance
MS-M-005 Reagent testing
MS-M-006 Cell quality monitoring
MS-M-007 GMP change room management
MS-M-008 Material entry and exit management
MS-M-009Personnel and material flow management
MS-M-010 Reagent and consumable material management
MS-M-011 SOPs and records management
MS-M-012 Cleanroom environment monitoring
MS-M-013 Cleanroom examination (safety, sanitation,
environment)
MS-M-014 Cleanroom state brand management
MS-C-001 Hospital matchmaking
MS-C-002 Document security
MS-H-001 Personnel training management
MS-H-002 Personnel training record
MS-H-003 Visitors’ reception standard
1.2 Operational standards (O e Operation, Q e Quality control, CL e Cleaning, E e Equipment)
1.2.1 Job responsibilities
SMP-H-001 Director of clinical cell culture room
SMP-H-002 Technical personnel of clinical cell culture room
SMP-H-003 Cleaning personnel of clinical cell culture room
SMP-H-004 Transport personnel of clinical-use cells
1.2.2 Operational procedures
OS-O-001 Standard operational procedure for cartilage tissue-engineered technique
SOPeO-003 Standard operational procedure for clinical-use cells/tissues transportation
1.2.3 SOPs (E e Equipment)
SOP-Q-001 Reagent and consumable material maintenance
SOP-Q-002 Reagent standards and tests
SOP-Q-003 Sterility test
SOP-Q-004 Mycoplasma tests
SOP-Q-005 Endotoxin tests
SOP-Q-006 PCR tests
SOP-O-001 Consumable material preparation
SOP-O-002 Cleanroom entry and exit
SOP-O-003 Sanitiser preparation and utilisation in cleanroom
SOP-O-004 Filter utilisation and tests
SOP-O-005 Unqualified products disposal
SOP-O-006 Waste disposal
SOP-CL-001 Protective clothing cleaning
SOP-CL-002 Cleaning tools utilisation
SOP-CL-003 GMP cleaning
SOP-CL-004 Water sink, floor drain and sterilisation
SOP-CL-005 Cleanroom sterilisation
SOP-CL-006 Pass box cleaning and sterilisation
SOP-CL-007 Pipeline cleaning
SOP-E-001 Refrigerator utilisation and maintenance
SOP-E-003 Water bath cleaning
SOP-E-004 High pressure steam steriliser utilisation
and cleaning
SOP-E-005Water processing system utilisation and
maintenance
SOP-E-006 Microscope utilisation
SOP-E-007 Pipette cleaning
SOP-E-008 Biological safety cabinet utilisation and cleaning
SOP-E-009 Centrifuge utilisation and cleaning
SOP-E-010 Cell incubator utilisation and cleaning
SOP-E-011 Laminar airflow system utilisation
SOP-E-012Air-conditioning system operation and
maintenance
SOP-E-013 Washing machine operation and maintenance
1.3 Technological standards
1.3.1 Quality standards
TS-Q-001 Processing environmental standards
TS-Q-002 Cell standards
1.3.2 Technological procedures
STP-O-001 Cartilage tissue-engineered technique
STP-O-002 Postoperative rehabilitation
2. Records
2.1 Batch records
RSOP-O-001 Cover of batch production
RSOP-O-002 Cover of batch packaging
RSOP-O-003 Chondrocytes culture
RSOP-O-003 Cleanroom environment monitoring
RSOP-O-004 Material counting
RSOP-O-005 Water processing
RSOP-O-006 Laminar airflow system operation
RSOP-Q-001 Bacterium examination
RSOP-Q-002 Mycoplasma examination
RSOP-Q-003 Endotoxin examination
RSOP-Q-004 Cell quality examination
RSOP-C-001 Patients documentation
RSOP-CL-001 GMP cleaning and sterilisation
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Table 3 (continued )
2.2 Production records
R SOP-O-002-1 Sanitiser preparation
R SOP-O-002-2 Sanitiser utilisation
RSOP-O-003 Filter changing
RSOP-O-004 Unqualified products disposal
RSOP-O-005 Waste disposal
RSOP-CL-001-1 Protective clothing cleaning and sterilisation
RSOP-CL-001-2 Protective shoes cleaning and sterilisation
RSOP-CL-002 Cleaning tools cleaning and sterilisation
R SOP-CL-004-1 Water sink cleaning and sterilisation
R SOP-CL-004-2 Floor drain cleaning and sterilisation
RSOP-CL-005 Cleanroom sterilisation
RSOP-CL-006 Pass box cleaning and sterilisation
RSOP-CL-007 Pipeline cleaning and sterilisation
RSOP-E-002 CO2 utilisation and changing
RSOP-E-003-1 Water bath cleaning
RSOP-E-004-1 High pressure steam steriliser operation
RSOP-E-007 Pipette cleaning
RSOP-E-009 Cell incubator operation
RSOP-E-011-1 Cleanroom temperature and humidity
RSOP-E-011-2 Cleanroom pressure difference
RSOP-E-1 Equipment repair
RSOP-E-2 Equipment maintenance
RSOP-E-3 Equipment calibration
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challenges:
Technical challengedDiversity
The seed cell issue
Recent regulation was limited to the terminal differenti-
ated adult tissue cells, but stem cells were still under strict
regulation. What if the adult stem cells were involved in the
new technique, e.g., bone marrow-derived mesenchymalFigure 4 Organisation chart of all participants involved in th
CFDA Z China Food and Drug Administration.stromal/stem cells used as the seed cells of the cartilage
[17e20]/bone/other TE technique? Another example is,
what if the seed cells are allogeneic cells, but with the
biomaterials we could avoid the systemic exposure [21]?
These different situations should be studied and discussed
on a case-by-case basis [22].
The scaffolds/cell carriers
A lot of natural and artificial biomaterials have been devel-
oped and are continuously upgraded for the TE technique,e application and execution of the Class III TE techniques.
64 W. Zhang et al.e.g., there is a branch of scaffolds or cell carrier choices for
ACI/MACI [23], and more biomaterials were designed to
improve the user experience and therapeutic efficacy [24].
The diversity of scaffold/cell carriers is also an issue that
required attention. The scaffolds were usually in a product
form, and meet different technique requirements.
Thus, the diversity of TE techniques continue to present
challenges to the management, and feedback to the trans-
lation procedures, e.g., different cells have their own char-
acters; different target tissue maintains their own
complexity; andmore importantly, the biggest challenge is to
clearly identify the maturity of different techniquesdthe
safety and efficacy is always paramount. However, the
translational path is not completelyblocked ifweknowwhere
to go, and whom to talk with regarding a novel technique.Challenges for each participantdroles and
responsibilities
All participants involved in the translational procedure
have their roles and responsibilities. We here list the
organisational chart in our case to illustrate the relation-
ships of all participants involved in the application and
execution of the class three TE techniques (Fig. 4).
Before clinical approval
In the initial application phase, the technique or product
should be evaluated for the safety and effectiveness. This
incubating phase is usually support by abundant funds, and a
group of people with specific expertise must be deployed to
the research & development (R&D), quality management,
clinical trials, regulation, and marketing position. The
technique provider, the contract manufacturer, and the
hospitals are involved in the application procedure, as the
application pathway shown in Fig. 4. Also, the medical ac-
ademic society, CFDA, and the health departments, are the
administration end of each unit, separately. The technique
provider here plays a role of intelligent/technical supporter
and incubator, as well as a coordinator of the application.
After clinical approval
The technique provider and contract manufacturer imple-
ment this medical technique together. The engineered tissue
is transferred between the hospital and contract manufac-
turer; the cell manufacturer is responsible for the cell quality
assurance. The technique provider supervises the quality of
the therapeutics as well as the implementation. The hospital
conducts the therapeutics and is responsible for the entire
procedure of bedside-laboratory-bedside. The governmental
health department tracks the hospital quality monitoring.
However, several challenges will be encountered when
launching the new technique to the public. Will clinicians and
patients recognise and accept the new technique? How should
both clinicians and technicians be trained? The technique
provider and universities take the responsibility to educate.
We addressed these problems using the following two ap-
proaches. We held regular training classes and academic
seminars for clinicians and technicians to introduce the basic
science and clinical operational techniques of cartilage TE
technique, to help them obtain full understanding and prep-
aration of the novel technique. In addition, we set uptranslational bases such as training centres and cell culture
laboratories at several tertiary hospitals. In this manner, TE
knowledge can be disseminated directly (not only to clini-
cians, but also patients), further train the clinicians and
technicians, and make carrying out clinical trials easier.
Conclusion
In this perspective paper, we provide a general outline of the
clinical translation of autologous cell-based TE techniques
and present efficient regulations in China. Our own cartilage
TE translational research is used as an example to illustrate
thepractical details. For techniqueproviders, the technique’s
safety and effectiveness should have been extensively inves-
tigated and verified. For hospitals using the specific tech-
nique, the qualification of hospitals andmedical professionals
should fulfil the requiredcriteria. The contractmanufacturing
procedures should be performed under complete manage-
ment systems. The culture cells should be extensively evalu-
ated and verified by self-examination and CFDA certified
testing. During the clinical translation process, multifactorial
challenges from scientific and social aspects will interrupt the
process, so multidisciplinary collaboration is needed from
researchers, hospitals, and regulatory bodies to enable more
promising results in the laboratory to translate into clinical
use, ultimately benefiting patients.
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